Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: Phase III randomised placebo controlled trial (MIR)

Kessler, David S.; MacNeill, Stephanie J.; Tallon, Deborah; Lewis, Glyn; Peters, Tim J.; Hollingworth, William; Round, Jeff; Burns, Alison; Chew-Graham, Carolyn A.; Anderson, Ian M.; Shepherd, Tom; Campbell, John; Dickens, Chris M.; Carter, Mary; Jenkinson, Caroline; Macleod, Una; Gibson, Helen; Davies, Simon; Wiles, Nicola J.

Abstract

Objective: To investigate the effectiveness of combining mirtazapine with Serotonin-Noradrenaline Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants for patients in primary care who had not responded to an antidepressant.
Design: A two parallel-group multi-centre, placebo controlled, randomised trial comparing the addition of mirtazapine to placebo for patients who had been adherent to an SSRI or SNRI for at least 6 weeks and were still depressed. Participants were stratified by centre and minimised by baseline Beck Depression Inventory score [BDI-II], gender and current psychological therapy. Participants, their General Practitioners (GPs), and the research team were blind to the allocation. Primary analyses compared the two groups as allocated without imputing missing data Setting: 106 general practices in 4 centres in the UK; Bristol, Exeter, Hull and North Staffordshire.
Participants: Between August 2013 and October 2015, we recruited 480 participants aged over 17 years, 69.1% of whom were female. Participants scored >13 using the BDI-II and fulfilled International Classification of Diseases [ICD]-10 criteria for depression. Exclusion criteria included bipolar disorder, psychosis and major alcohol/substance abuse. 431 (89.8%) were included in the (primary) 12-week follow-up.
Intervention: 241 participants were randomised to mirtazapine and 239 to placebo, both given in addition to their usual SSRI/SNRI medication. They were followed up at 12, 24 and 52 weeks.
Main outcome measures: Depressive symptoms at 12 weeks post-randomisation, measured using the BDI-II score as a continuous variable. Secondary outcomes include measures of anxiety, quality of life and adverse effects at 12, 24 and 52 weeks.
Results: BDI-II scores at 12 weeks were lower in the mirtazapine group after adjustment for baseline BDI-II and minimisation/stratification variables, although the confidence interval included the null (mean (SD) BDI-II scores at 12 weeks: 18.0 (12.3) in the mirtazapine group; 19.7 (12.4) in the placebo group; adjusted difference between means -1.83 (95% confidence interval: -3.92 to 0.27, p=0.087)). Adverse effects were more frequent in the mirtazapine group and associated with stopping the trial medication.
Conclusion: This study did not find evidence of a clinically important benefit for mirtazapine in addition to an SSRI or SNRI antidepressant over placebo in a treatment resistant group of primary care patients with depression. This remains an area of important unmet need where there is limited evidence of effective treatment options.

Citation

Kessler, D. S., MacNeill, S. J., Tallon, D., Lewis, G., Peters, T. J., Hollingworth, W., …Wiles, N. J. (2018). Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: Phase III randomised placebo controlled trial (MIR). BMJ, 363, Article k4218. https://doi.org/10.1136/bmj.k4218

• Journal Article Type: Article
• Acceptance Date: Sep 28, 2018
• Online Publication Date: Oct 31, 2018
• Publication Date: Oct 31, 2018
• Deposit Date: Dec 5, 2018
• Publicly Available Date: Dec 6, 2018
• Journal: BMJ
• Print ISSN: 0959-8138
• Electronic ISSN: 1756-1833
• Publisher: BMJ Publishing Group
• Peer Reviewed: Peer Reviewed
• Volume: 363
• Article Number: k4218
• DOI: https://doi.org/10.1136/bmj.k4218
• Keywords: General Medicine
• Public URL: https://hull-repository.worktribe.com/output/1173631
• Publisher URL: https://www.bmj.com/content/363/bmj.k4218